ubmslateRN-logo-ubm

RN Mobile Menu

Topics:

Rheumatology Network

Review, Review, Review

It is imperitive that physicians review medications with fracture patients. Various medication classes post a risk of repeat fracture. (©CatherineLall/Shutterstock.com)

Recent Content

“Not treating patients with osteoporosis drugs after a fracture would be like discharging a patient after a myocardial infarction without drugs to prevent a subsequent infarction,” researchers write in JAMA Internal Medicine.

©Addyvanich/Shutterstock.com

Improving care for high-need, high-cost patients is an imperative for patients and the healthcare system. Programs are in development, NEJM perspective reports.

©wavebreakmedia/Shutterstock.com

A NEJM study of three clinical trials for ixekizumab to treat mild to moderate psoriasis, shows that the IL-17A inhibitor performs well through 60 weeks.

©Watchara/Shutterstock.com

To better understand Mendelian randomization and how it touches rheumatological conditions, researchers have analyzed existing results revealing a causal relationship.

©CherylCasey/Shutterstock.com

Cushingoid appearance is a side effect of glucocorticoid use, but to date, there has been little knowledge about how glucocorticoids can change fat mass and redistribution.

©MaxxStudio/Shutterstock.com

Triple therapy in RA is infrequent, despite mounting evidence that this more cost-effective option might be as effective as treatment intensification with biologic disease-modifying antirheumatic drugs.

©ImagePointFr/Shutterstock.com

Rheumatoid arthritis patients who are in remission or have stable low disease activity should continue TNFi therapy to control flares, study finds.

By clicking Accept, you agree to become a member of the UBM Medica Community.